Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
46,338,765
-
Share change
-
+2,820,297
-
Total reported value
-
$1,790,195,856
-
Put/Call ratio
-
44%
-
Price per share
-
$38.64
-
Number of holders
-
170
-
Value change
-
+$97,400,922
-
Number of buys
-
87
-
Number of sells
-
69
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2021
As of 31 Dec 2021,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
170 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,338,765 shares.
The largest 10 holders included
FMR LLC, RTW INVESTMENTS, LP, BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, WELLINGTON MANAGEMENT GROUP LLP, Redmile Group, LLC, RA CAPITAL MANAGEMENT, L.P., EVENTIDE ASSET MANAGEMENT, LLC, and CITADEL ADVISORS LLC.
This page lists
170
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.